Viñolas N, Mezquita L, Corral J, Cobo M, Gil-Moncayo F, Paz-Ares L, Remon J, Rodríguez M, Ruano-Raviña A, Conde E, Majem M, Garrido P, Felip E, Isla D, de Castro J. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.. Clinical & Translational Oncology. 2024; 26(2)DOI:10.1007/s12094-023-03262-x. PMID:37490262. IF:2.500(Q3/6D).

Campos F, Téres R, Sebio A, Bettim BB, Martinez-Trufero J. Survival Differences of Patients with Resected Extraskeletal Osteosarcoma Receiving Two Different (Neo)Adjuvant Chemotherapy Regimens: A Systematic Review and Meta-analysis.. CLINICAL ONCOLOGY. 2023; 35(12)DOI:10.1016/j.clon.2023.09.009. PMID:37777356. IF:3.200(Q2/5D).

Nadal E, Rodríguez-Abreu D, Simó M, Massutí B, Juan O, Huidobro G, López R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilariño N, Navarro V, Bruna J. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(28)DOI:10.1200/JCO.22.02561. PMID:37603816. IF:42.100(Q1/1D).

Casanovas-Álvarez A, Sebio-Garcia R, Ciendones M, Cuartero J, Estanyol B, Padrós J, García-Valdecasas B, Barnadas A, Masia J. Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial.. PHYSICAL THERAPY. 2023; 103(9)DOI:10.1093/ptj/pzad062. PMID:37318267. IF:3.500(Q1/1D).

Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, Barrett JC, Hodge R, McKeown A, Hartmaier RJ, Chmielecki J, Papadimitrakopoulou VA, Ramalingam SS. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.. CLINICAL CANCER RESEARCH. 2023; 29(17)DOI:10.1158/1078-0432.CCR-22-3146. PMID:37379430. IF:10.400(Q1/1D).

Escuin D, López-Vilaró L, Bell O, Mora J, García-Valdecasas B, Moral A, Clos M, Boronat L, Arqueros C, Barnadas A. Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients.. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(17)DOI:10.3390/ijms241713293. PMID:37686099. IF:4.900(Q1/3D).

Fumagalli, C, Orellana, R, Bagué, S, Ferré, M, Gonzalez, A, Catasus, L, Llauger, J, Peiró, A, Alarcón, PZ, Majercakova, K, Terés, R, Karanian-Philippe, M, Tirode, F, Antonescu, CR. YAP1::KMT2A-Rearranged Sarcoma: Report of a New Case With Unusual Morphology and Immunohistochemical Features. GENES CHROMOSOMES & CANCER. 2025; 64(7)DOI:10.1002/gcc.70059. PMID:40879254. IF:2.800(Q2/5D).

Paz-Ares, L, Veillon, R, Majem, M, Zhou, CC, Tang, KJ, Kim, SW, Richardson, G, Girard, N, Sanborn, RE, Mansfield, AS, Park, K, Schuchard, J, Diels, J, Sermon, J, Bhattacharya, A, Lorenzini, P, Wortman-Vayn, H, Knoblauch, RE, Agrawal, T, Baig, M, Ono, A, Sabari, JK. Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC. LUNG CANCER. 2026; 213DOI:10.1016/j.lungcan.2025.108788. PMID:41671629. IF:4.400(Q1/2D).

Mateos, L, Jiménez-Fonseca, P, Gallego, J, Lecumberri, A, Custodio, A, de Castro, EM, San Gil, RH, Montes, AF, Limon, ML, Vidal-Tocino, R, Cano, JM, Robles, JL, Gil, M, Eyzaguirre, DA, Zafra, GM, Mérida-García, AJ, Fernández, AF, Fernández, PR, Hierro, C, Riesco, MC, Araque, MG, Martín, MR, Pimentel, P, Visa, L, Cerdá, P, Granja, M, Blanco, ABR, Gutiérrez, L, Carmona-Bayonas, A. Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis. BRITISH JOURNAL OF CANCER. 2026; 134(3)DOI:10.1038/s41416-025-03264-2. PMID:41298815. IF:6.800(Q1/2D).

López-López, C, de Castro, EM, Montes, AF, Orozco, EJ, Peraita, SL, Vera, R, Cerdá, P, Calvo, M, Paredes, BG, de Mena, ML, La Casta, A, Gallego, J, Adeva, J, Cano, JMC, Ruiz-Casado, A, Vidal-Tocino, R, García-García, T, Pazo-Cid, R, Garrote, MR, Sastre, J. Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry. Clinical & Translational Oncology. 2026; 28(2)DOI:10.1007/s12094-025-04010-z. PMID:40782167. IF:2.500(Q3/6D).

Molassiotis, A, Jordan, K, Karthaus, M, Dranitsaris, G, Roeland, EJ, Schwartzberg, L, Stimamiglio, V, Alonzi, A, Tilola, SO, Bonizzoni, E, Vázquez, EB, Buchler, T, Cheng, Y, Christoph, DC, Alfonso, PG, Lu, X, Majem, M, Mavroudis, D, Syrigos, K, Tomlins, E, Zhou, Z, Zimovjanová, M, Aapro, M. Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial. ANNALS OF ONCOLOGY. 2026; 37(2)DOI:10.1016/j.annonc.2025.10.017. PMID:41110696. IF:65.400(Q1/1D).

Gonzalez-Cao, M, Berciano-Guerrero, MA, Muñoz-Couselo, E, Manzano, JL, Cerezuela-Fuentes, P, Crespo, G, Soria, A, de Miguel, PA, Sanz, LG, de la Rosa, CA, Castaño, AG, Puértolas, T, Espinosa, E, Medina, J, Bellido, L, Berrocal, A, Majem, M, Castro, RL, Fernandez, LA, Garcia, F, de la Borbolla, MR, Algarra, SM, Márquez-Rodas, I. Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry. Clinical & Translational Oncology. 2026; 28(2)DOI:10.1007/s12094-025-04018-5. PMID:40841506. IF:2.500(Q3/6D).

Rueda, A, Garcia-Leon, A, Arena, LA, Mendoza, JI, Avino, A, Fabrega, C, Eritja, R, Paez, D, Alba-Castellon, L, Vazquez, E, Villaverde, A, Mangues, R, Casanova, I, Unzueta, U. Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates. Materials Today Bio. 2026; 36DOI:10.1016/j.mtbio.2025.102698. PMID:41560806. IF:10.200(Q1/1D).

Borrego, MR, Lopez-Bravo, DP, Vila, MM, Pérez-García, JM, Fernández, M, Tormo, SB, García-Saenz, JA, Lema, L, Garau, I, Cortez, P, Torres, AA, Conejo, EA, Calvo, I, Ferrer, N, Blancas, I, Amillano, K, Santasusagna, S, Benderra, MA, Alcalá-Lopez, D, Antonarelli, G, Sampayo-Cordero, M, Llombart-Cussac, A, Cortés, J. Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study. EUROPEAN JOURNAL OF CANCER. 2026; 233DOI:10.1016/j.ejca.2025.116161. PMID:41371050. IF:7.100(Q1/2D).

Toledano-Fonseca, M, Cano-Osuna, MT, Elez, E, Soto-Alsar, J, Paáez, D, Fernández-Montes, A, Graña, B, Salud, A, Yubero, A, Macías, I, Quintero, G, López-López, C, Fernández-Rodríguez, T, García-Ortiz, MV, Sastre, J, García-Alfonso, P, Rodríguez-Ariza, A, Aranda, E. Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2026; 56(1)DOI:10.1111/eci.70103. PMID:40747746. IF:3.600(Q1/2D).

Mirallas, O, Ruiz-Pace, F, Velilla, G, Gómez-Puerto, D, Gorria, T, Yaringaño, J, Martínez-Monino, A, López-Valbuena, D, Vaz, MA, Hernandez, A, Martínez-Saez, E, Sorolla, MA, Castro-Henriques, M, Bardaji, JL, Di Muzio, A, Gallego, O, Martínez-García, M, Domenech, M, Carles, J, Balaña, C, Pineda, E, Dienstmann, R, Vieito, M, Sepúlveda, JM. Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study. npj Precision Oncology. 2026; 10(1)DOI:10.1038/s41698-025-01247-3. PMID:41495434. IF:8.000(Q1/2D).

O'Byrne, K, Esteban, E, Lee, CL, Hegmane, A, Volovat, C, Lo Russo, G, Ziogas, D, Atmaca, A, Sebastian, M, Majem, M. A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. Future Oncology. 2025; 21(30)DOI:10.1080/14796694.2025.2597404. PMID:41383151. IF:2.600(Q3/6D).

Salazar, J, Arranz, MJ, Martin-Broto, J, Serra, M, Palmerini, E, Martínez-García, J, Juan-Ribelles, A, Andion, M, Martinez-Trufero, J, Gutiérrez, G, Echebarria-Barona, A, Vaz-Salgado, MA, Regueiro, A, Alvarez, R, Valverde, C, Luna, P, Blay, P, Sebio, A. VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol. Pharmaceuticals. 2025; 18(12)DOI:10.3390/ph18121855. PMID:41471344. IF:4.800(Q1/2D).

Tsuboi, M, Wakelee, H, Spicer, JD, Gao, S, Liberman, M, Kato, T, Chen, KN, Dooms, C, Majem, M, Martinengo, GL, Bylicki, O, Abreu, DR, Halmos, B, Jones, DR, Chaft, J, Reck, M, Jense, E, Keller, SM, Samkari, A, Garassino, MC. Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.10.607. PMID:. IF:65.400(Q1/1D).

Molina-Pérez, MA, Martínez-Recio, S, Barba, A, Portu, M, Sanz-Beltran, J, Majem, M. Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy?. Translational Lung Cancer Research. 2025; 14(11)DOI:10.21037/tlcr-2025-866. PMID:41367561. IF:3.500(Q1/3D).